ProCE Banner Activity

CME

Clinical Findings and Approvals: PARP Inhibitor Strategies in Prostate Cancer

Video

On-demand recording of expert faculty presentations and case discussions on new clinical findings and regulatory approvals of PARP inhibitors in combination to treat patients with prostate cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: February 07, 2024

Expiration: February 06, 2025

Share

Faculty

Neeraj Agarwal

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Andrew Armstrong

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA

Target Audience

This educational program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Prostate Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the medical need and rationale for PARP inhibitors and PARP inhibitor–based combinations in prostate cancer

  • Assess homologous recombination repair mutations and BRCA mutations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer

  • Plan PARP inhibitor–based combination therapy for patients with advanced prostate cancer, considering HRRm and BRCAm status, recent guideline updates, FDA approvals, and expert recommendations

  • Identify patients with prostate cancer eligible for enrollment on clinical trials investigating PARP inhibitor–based combinations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Neeraj Agarwal, MD, FASCO, has no relevant financial relationships to disclose.

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Andrew Armstrong, MD, ScM, FACP: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, GoodRx, Epic Sciences, Exelixis, Janssen, Merck, Myovant, Novartis, Pfizer.

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Tanya B. Dorff, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Janssen, Sanofi.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 07, 2024, through February 06, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.